RxDoctor Payments Data

Paul Wells, MD

Internal Medicine · Angleton, TXNPI 1669684189

Payments from drug & device makers

$434in general payments, 2019–2025

Across 18 payments — averaging $24.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$169
  • Lilly USA, LLC$92
  • GSK$79
  • Kowa Pharmaceuticals America, Inc.$34
  • Biohaven Pharmaceutical Holding Company Ltd.$19
  • Abbott$15
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$434 in reported general payments places this provider in the 55th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$51,695
Medicare patients
112
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol49$35,570
EliquisApixaban24$23,077
XareltoRivaroxaban24$21,227
JanuviaSitagliptin Phosphate24$19,341
OzempicSemaglutide13$12,298
Armour ThyroidThyroid,pork116$11,485
MyrbetriqMirabegron21$10,142
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen250$7,750
ArexvyRsvpref3 Antigen/As01e/Pf22$6,381
Np ThyroidThyroid,pork68$6,199
Dexlansoprazole DrDexlansoprazole18$5,412
Levothyroxine Sodium516$5,068
ShingrixVaricella-Zoster Ge/As01b/Pf17$3,352
Gabapentin203$3,065
Losartan Potassium166$2,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$169$35,57049 claims
Johnson & JohnsonXarelto$12$21,22724 claims
AbbVieArmour Thyroid, Synthroid$14$12,843160 claims
GSKArexvy, Shingrix$79$9,73339 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Angleton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →